MINDCURE Announces Experienced Finance Executive Michael Wolfe as CFO and appoints Larissa Chaikowsky to its Board of Directors

Mr. Wolfe has extensive capital markets and debt and equity financing experience; Ms. Chaikowsky, the COO at BMO Wealth Management, has significant expertise in corporate governance, human resources and operational risk management

VANCOUVER, BC, April 22, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") a leader in advanced proprietary technology for psychedelic therapy, is pleased today to announce the hiring of Michael Wolfe as the company's new Chief Financial Officer. Mr. Wolfe possesses over 30 years of financial leadership and private equity experience and most recently served as the CFO at Baylin Technologies, a TSX-listed company in the wireless communications industry. In an additional appointment also announced today, MINDCURE has named Larissa Chaikowsky to its Board of Directors. Stephen Inouye will be stepping down from his position on the Board, as well as from the CFO role for personal reasons to make way for Ms. Chaikowsky and Mr. Wolfe, respectively.

Mr. Wolfe's experience with raising capital through markets, financial institutions, and investment banks will be important as MINDCURE continues to build its team, its technology, and its leadership position within the psychedelics industry.  He has a successful track record in mergers and acquisitions, growth financings and recapitalizations in diverse industries such as cable, manufacturing and global logistics. "I am honoured to be joining MINDCURE at this exciting stage of company growth. Mrs. Ramsden is an impressive CEO and so is the team she is building around her," said Michael Wolfe, MINDCURE CFO. "In addition to having worked with established mid-market companies, I was the CFO of an early-stage health app and am excited by the potential of iSTRYM to serve a large global market in need."

"I would first like to thank Stephen Inouye for his instrumental role in our first chapter at MINDCURE," said MINDCURE CEO and President Kelsey Ramsden. "We continue to build a world-class executive team over the past months, with a particular focus on what we intend to do better than anybody else with our digital therapeutics strategy driving near-term revenue and pre-clinical research underway. Mr. Wolfe has a strong background in the capital markets, and his particular financial expertise with regards to capital raising, acquisitions and the public markets are of immense value to MINDCURE."

Ms. Chaikowsky currently serves as the COO of US Wealth Management at the BMO Financial Group and has served a variety of leadership roles at the company through her 15+ year career there. "I am very excited to join the MINDCURE Board of Directors. I am passionate about innovation, and particularly around mental health care through psychedelics," said Larissa Chaikowsky. "Mrs. Ramsden has assembled an impressive Board and I look forward to bringing my expertise within corporate governance, operational risk management, and human resources to MINDCURE as its rapid growth continues."

"Ms. Chaikowsky is a premier executive with a stellar track record of success. She is a no-nonsense and passionate leader with very relevant experience for us in regulated industries, particularly in the United States," continued Mrs. Ramsden. "We will lean on her significantly for her expertise with internal human resource structure as well as with her network and connections in banking and the capital markets."

About Michael Wolfe:

Mr. Wolfe has over 30 years' experience in finance, accounting. private equity and business valuation. He was most recently the Chief Financial Officer of Baylin Technologies Inc., a TSX listed company in the wireless communications industry.  Prior to joining Baylin, Michael was the Chief Financial Officer of several mid-market Canadian companies including Masstech Group Inc., a software company in the broadcast industry. As a General Partner at VenGrowth Capital Partners Inc., Michael had a successful track record in acquisitions, management buyouts, growth financings and recapitalizations in diverse industries such as cable, broadcast, manufacturing, insurance, oil field services and global logistics.

Mr. Wolfe has also served as a director for several private and public companies, including as a member of audit and other independent committees. He earned a CPA, CA designation, a Chartered Business Valuator designation, an MBA from McMaster University, and a BA (Business and Economics) from the University of Western Ontario.

About Larissa Chaikowsky:

Larissa Chaikowsky is the Chief Operating Officer for the U.S. Wealth Management business at BMO. She leads the National Office Teams and oversees the planning, development and implementation of product and service strategies for BMO Financial Group's U.S. Wealth businesses. Prior to this role, Larissa was the U.S. Chief Human Resources Officer for BMO Financial Group. She oversaw the strategic and operational governance processes of the U.S. HR organization. She executed enterprise HR overseeing and coordinating human resources related matters as they pertain to: U.S. regulatory agencies, and U.S. mergers and acquisitions. Larissa had a leadership role with the Human Resources Committee of the BMO Financial Corp board of Directors and the Benefits Investment Committee. She also chaired the U.S. Compensation Oversight Committee and the U.S. Benefits Administration Committee.

During her fifteen-year tenure with BMO, Larissa has held several senior positions that have played a role in helping redefine the BMO brand and improving the business practices of Technology and Operations, Human Resources and Corporate Strategy. Larissa received her Bachelor of International Business and Relations from the Sprott School of Business and holds an MBA from the Richard Ivey School of Business.

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute "forward-looking information" within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as "anticipate", "believe", "could", "estimate", "expect", "feel", "intend", "may", "plan", "predict", "project", "subject to", "will", "would", and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: MINDCURE's digital therapeutics strategy driving near-term revenues; Mr. Wolfe's strong background and expertise being immense value to MINDCURE; Ms. Chaikowsky bringing her expertise to MINDCURE as rapid growth continues; and MINDCURE leaning on Ms. Chaikowsky significantly for her expertise with human resources, network and connections.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE's business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE's business; there will be a demand for MINDCURE's products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; MINDCURE's digital therapeutics strategy will drive near-term revenues; Mr. Wolfe will provide immense value to MINDCURE; Ms. Chaikowsky will bring her expertise to MINDCURE as rapid growth continues; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE's industry and MINDCURE's business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE's investments, results of operations, financial condition, and MINDCURE's ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; MINDCURE's digital therapeutics strategy may not drive near-term revenues; Mr. Wolfe may not provide immense value to MINDCURE; Ms. Chaikowsky may not bring her expertise to MINDCURE as rapid growth continues;; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under "Risk Factors" in MINDCURE's final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management's current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.